Global and gene-specific promoter methylation analysis in primary hyperparathyroidism

Epigenetics

Volumn 8, Issue 6, 2013, Pages 646-655

  Sulaiman, Luqman ^a   Juhlin, C Christofer ^a   Nilsson, Inga Lena ^a   Fotouhi, Omid ^a   Larsson, Catharina ^a   Hashemi, Jamileh ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

APC; CpG islands; DNA promoter methylation; Parathyroid tumors; Pyrosequencin; RASSF1A; SFRP1; Wnt signaling; catenin

Indexed keywords

APC PROTEIN; BETA CATENIN; BISULFITE;

ADENOMA; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MALE; METABOLISM; PARATHYROID GLAND; PARATHYROID TUMOR; PATHOLOGY; PRIMARY HYPERPARATHYROIDISM; PROMOTER REGION;

ADENOMA; ADULT; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; PROMOTER REGIONS, GENETIC;

EID: 84891676806     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.24823     Document Type: Article

References (54)

1. DeLellis RA, Lloyd RV, Heitz PU, C E. Pathology and Genetics of the Tumours of Endocrine Organs, WHO Classification of Tumours. Lyon: IARC Press, 2004.
2. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276:404-7; PMID:9103196; http://dx.doi.org/10.1126/science.276.5311.404
3. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997; 6:1177-83; PMID:9215690; http://dx.doi.org/10.1093/hmg/6.7.1177
4. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidismjaw tumor syndrome. Nat Genet 2002; 32:676-80; PMID:12434154; http://dx.doi.org/10.1038/ng1048
5. Carling T, Rastad J, Szabó E, Westin G, Akerström G. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85:2000-3; PMID:10843188; http://dx.doi.org/10.1210/jc.85.5.2000
6. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51:328-36; PMID:8995751; http://dx.doi.org/10.1038/ki.1997.41
7. Carling T, Szabo E, Bai M, Ridefelt P, Westin G, Gustavsson P, et al. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 2000; 85:2042-7; PMID:10843194; http://dx.doi.org/10.1210/jc.85.5.2042
8. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429:457-63; PMID:15164071; http://dx.doi.org/10.1038/nature02625
9. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28; PMID:12042769
10. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168-74; PMID:10729832; http://dx.doi.org/10.1016/S0168-9525(99)01971-X
11. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22:4632-42; PMID:15542813; http://dx.doi.org/10.1200/JCO.2004.07.151
12. Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenström J, Höög A, et al. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. PLoS One 2010; 5:e9472; PMID:20208994; http://dx.doi.org/10.1371/journal.pone.0009472
13. Starker LF, Svedlund J, Udelsman R, Dralle H, Akerström G, Westin G, et al. The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosomes Cancer 2011; 50:735-45; PMID:21638518; http://dx.doi.org/10.1002/gcc.20895
14. Hewitt KM, Sharma PK, Samowitz W, Hobbs M. Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 2007; 116:928-33; PMID:18217513
15. Hahn MA, Howell VM, Gill AJ, Clarkson A, Weaire-Buchanan G, Robinson BG, et al. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocr Relat Cancer 2010; 17:273-82; PMID:20026646; http://dx.doi.org/10.1677/ERC-09-0291
16. Sulaiman L, Haglund F, Hashemi J, Obara T, Nordenström J, Larsson C, et al. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors. PLoS One 2012; 7:e46325; PMID:23029479; http://dx.doi.org/10.1371/journal.pone.0046325
17. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003; 22:924-34; PMID:12584572; http://dx.doi.org/10.1038/sj.onc.1206123
18. Di Vinci A, Perdelli L, Banelli B, Salvi S, Casciano I, Gelvi I, et al. p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer 2005; 114:414-21; PMID:15578730; http://dx.doi.org/10.1002/ijc.20771
19. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 2008; 123:161-7; PMID:18398837; http://dx.doi.org/10.1002/ijc.23519
20. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 2003; 9:3635-40; PMID:14506151
21. Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93:691-9; PMID:11333291; http://dx.doi.org/10.1093/jnci/93.9.691
22. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17:45-51; PMID:17208432; http://dx.doi.org/10.1016/j.gde.2006.12.007
23. Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Bränström R, et al. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol 2009; 34:481-92; PMID:19148484
24. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36:417-22; PMID:15034581; http://dx.doi.org/10.1038/ng1330
25. Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M, et al. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 2009; 18:2694-700; PMID:19789364; http://dx.doi.org/10.1158/1055-9965.EPI-08-0821
26. Costa VL, Henrique R, Ribeiro FR, Carvalho JR, Oliveira J, Lobo F, et al. Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 2010; 5:343-51; PMID:20421722; http://dx.doi.org/10.4161/epi.5.4.11749
27. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92; PMID:6185846; http://dx.doi.org/10.1038/301089a0
28. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2(Suppl 1):S4-11; PMID:16341240; http://dx.doi.org/10.1038/ncponc0354
29. Esteller M. Aberrant DNA methylation as a cancerinducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45:629-56; PMID:15822191; http://dx.doi.org/10.1146/annurev.pharmtox.45.120403.095832
30. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012; 22:50-5; PMID:22402447; http://dx.doi.org/10.1016/j.gde.2012.02.008
31. Gavert N, Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. J Cell Biochem 2007; 102:820-8; PMID:17854061; http://dx.doi.org/10.1002/jcb.21505
32. Zeki K, Spambalg D, Sharifi N, Gonsky R, Fagin JA. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. J Clin Endocrinol Metab 1994; 79:1317-21; PMID:7962323; http://dx.doi.org/10.1210/jc.79.5.1317
33. Hayes MJ, Thomas D, Emmons A, Giordano TJ, Kleer CG. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 2008; 14:4038-44; PMID:18593979; http://dx.doi.org/10.1158/1078-0432.CCR-07-4379
34. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001; 7:1998-2004; PMID:11448917
35. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000; 60:4366-71; PMID:10969779
36. Björklund P, Akerström G, Westin G. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. J Clin Endocrinol Metab 2007; 92:338-44; PMID:17047023; http://dx.doi.org/10.1210/jc.2006-1197
37. Cetani F, Pardi E, Banti C, Collecchi P, Viacava P, Borsari S, et al. Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. Endocr Relat Cancer 2010; 17:1-6; PMID:19755524; http://dx.doi.org/10.1677/ERC-09-0147
38. Greenwald BD, Harpaz N, Yin J, Huang Y, Tong Y, Brown VL, et al. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 1992; 52:741-5; PMID:1346256
39. Zhang HY, Rumilla KM, Jin L, Nakamura N, Stilling GA, Ruebel KH, et al. Association of DNA methylation and epigenetic inactivation of RASSF1A and betacatenin with metastasis in small bowel carcinoid tumors. Endocrine 2006; 30:299-306; PMID:17526942; http://dx.doi.org/10.1007/s12020-006-0008-1
40. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65:3497-508; PMID:15867337; http://dx.doi.org/10.1158/0008-5472.CAN-04-4088
41. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem 2002; 383:907-14; PMID:12222680; http://dx.doi.org/10.1515/BC.2002.097
42. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25:315-9; PMID:10888881; http://dx.doi.org/10.1038/77083
43. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001; 20:1509-18; PMID:11313894; http://dx.doi.org/10.1038/sj.onc.1204175
44. Li J, El-Naggar A, Mao L. Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 2005; 104:771-6; PMID:15959912; http://dx.doi.org/10.1002/cncr.21215
45. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, Veeck J, et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 2007; 26:5680-91; PMID:17353908; http://dx.doi.org/10.1038/sj.onc.1210345
46. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006; 25:3479-88; PMID:16449975; http://dx.doi.org/10.1038/sj.onc.1209386
47. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178-86; PMID:19151715; http://dx.doi.org/10.1038/ng.298
48. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-98; PMID:17339880; http://dx.doi.org/10.1038/nrg2005
49. Sulaiman L, Nilsson IL, Juhlin CC, Haglund F, Höög A, Larsson C, et al. Genetic characterization of large parathyroid adenomas. Endocr Relat Cancer 2012; 19:389-407; PMID:22454399; http://dx.doi.org/10.1530/ERC-11-0140
50. Rosen JE, Costouros NG, Lorang D, Burns AL, Alexander HR, Skarulis MC, et al. Gland size is associated with changes in gene expression profiles in sporadic parathyroid adenomas. Ann Surg Oncol 2005; 12:412-6; PMID:15915376; http://dx.doi.org/10.1245/ASO.2005.03.103
51. Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenström J, Forsberg L, et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 2007; 14:501-12; PMID:17639063; http://dx.doi.org/10.1677/ERC-07-0021
52. Sulaiman L, Nilsson IL, Juhlin CC, Haglund F, Höög A, Larsson C, et al. Genetic characterization of large parathyroid adenomas. Endocr Relat Cancer 2012; 19:389-407; PMID:22454399; http://dx.doi.org/10.1530/ERC-11-0140
53. Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349:1722-9; PMID:14585940; http://dx.doi.org/10.1056/NEJMoa031237
54. Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, Alimov A, et al. Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer 2006; 13:509-23; PMID:16728578; http://dx.doi.org/10.1677/erc.1.01058